Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer

Inclusion Criteria:

* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC), including any of the following histologic subtypes:

  * Squamous cell carcinoma
  * Adenocarcinoma
  * Large cell undifferentiated carcinoma
* Stage II or IIIA disease
* Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral Computerized Axial Tomography (CT) scan
* No tumor involving the superior sulcus (e.g., Pancoast tumor)
* Karnofsky performance status 70-100%
* Absolute neutrophil count ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Creatinine ≤ 2 mg/dL
* Bilirubin \< 2 mg/dL
* Aspartate aminotransferase (AST) \< 3 times upper limit of normal

Exclusion Criteria:

* Pregnant or nursing

  * No nursing during and for ≥ 4 weeks after completion of study treatment
* Positive pregnancy test
* Fertile female patients must use 2 effective methods of contraception 4 weeks before, during, and for 4 weeks after completion of study treatment
* Fertile male patients must use effective barrier contraception during and for 4 weeks after completion of study treatment
* Blood, sperm, or ova donation during study treatment
* Post obstructive pneumonia
* Other serious infection or medical illness that would preclude study participation
* Other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other malignancy that is unlikely to affect survival for the next 3 years
* Less than 5 years since prior resection of lung disease
* Prior systemic chemotherapy or radiotherapy for non-small cell lung cancer (NSCLC)
* Other concurrent chemotherapy or radiotherapy
* Concurrent hormonal therapy or immunotherapy
* Other concurrent anticancer therapy
* Other concurrent investigational agents
* Concurrent participation in another clinical study